Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and whatnot has predictably returned. To cope, we are undertaking what is surely a familiar ritual by now — brewing cups of stimulation to fire up the neurons. We need all the help we can get. Our choice today, by the way, is hazelnut creme, for those tracking this sort of thing. And now, here are a few tidbits to help you along. Hope your day is smashing and do stay in touch.

Experimental drugs from Roche (RHHBY) and Eli Lilly (LLY) failed to halt Alzheimer’s disease in their latest test in a blow to people whose genes make them particularly vulnerable to the illness, Reuters reports. The studies focused on rare autosomal dominant Alzheimer’s disease, which is caused by gene mutations that follow generations of families. A pair of separate Roche studies of its drug against a form of Alzheimer’s disease not directly caused by gene mutations would continue. It is due to produce results in 2022.


Every Democratic presidential candidate agrees the federal government should take a far more aggressive approach to lowering drug costs — including letting Medicare negotiate prices. But beyond that plank, there are quite a few differences between the candidates when it comes to taking on the pharmaceutical industry, STAT notes. STAT questioned seven candidates, who cited insulin and EpiPens as the big boogeymen of drug pricing. The candidates also lumped pharma in with oil and insurance companies as the industries that have corrupted Washington.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!